Skip to main content

Table 5 Median of overall survival analysis of patients who only received intervention: (A) BCc1 nanomedicine or Placebo without chemotherapy. (B) Death percentage analysis of patients who only received intervention: BCc1 nanomedicine or Placebo without chemotherapy

From: A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients

Group Metastatic Non-metastatic
Total number BCc1(n = 19) Placebo (n = 11) BCc1(n = 18) Placebo (n = 10)
(A) Median of overall survival analysis
Median (days) 174 52 442 454
Std. error 46.75 46.64 41.43 44.635
Median 95% CI (lower) 118.40 0 361 366
Median 95% CI (upper) 229.59 113.69 523 541
P-value for test of equality of survival distributions 0.042 0.053
HR
(BCc1/Placebo)
0.500 0.324
Stage (n)
 I 0 0 3 1
 II 0 0 3 4
 III 0 0 8 3
 IIII 19 11 0 0
(B) Death rate analysis median of overall survival analysis
Death rate (%) 49 63 13 30
  1. Test of equality of survival distributions for (Bcc1 an0d placebo groups) assay with Log Rank (Mantel-Cox)